← Eichor
Study identifier: NCT07236203 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Condition: Large B-Cell Lymphoma  ·  Sponsor: Fudan University

PhaseN/A
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

This description comes directly from the study's public registry record.

Talk to the study team

Chuanxu Liu, M.D  ·  021-64175590  ·  liuchuanxu@shca.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07236203